Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Net Cash Flow (2016 - 2025)

Wave Life Sciences (WVE) has disclosed Net Cash Flow for 11 consecutive years, with $405.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 4737.5% year-over-year to $405.9 million, compared with a TTM value of $300.0 million through Dec 2025, up 194.35%, and an annual FY2025 reading of $300.0 million, up 194.35% over the prior year.
  • Net Cash Flow was $405.9 million for Q4 2025 at Wave Life Sciences, up from -$12.2 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $405.9 million in Q4 2025 and bottomed at -$88.8 million in Q1 2022.
  • Average Net Cash Flow over 5 years is $20.9 million, with a median of -$15.8 million recorded in 2024.
  • Peak annual rise in Net Cash Flow hit 4737.5% in 2025, while the deepest fall reached 205.34% in 2025.
  • Year by year, Net Cash Flow stood at $26.7 million in 2021, then plummeted by 131.95% to -$8.5 million in 2022, then surged by 806.46% to $60.4 million in 2023, then crashed by 114.5% to -$8.8 million in 2024, then soared by 4737.5% to $405.9 million in 2025.
  • Business Quant data shows Net Cash Flow for WVE at $405.9 million in Q4 2025, -$12.2 million in Q3 2025, and -$34.6 million in Q2 2025.